PT  - JOURNAL ARTICLE
AU  - Dekker, Mark M.
AU  - Coffeng, Luc E.
AU  - Pijpers, Frank P.
AU  - Panja, Debabrata
AU  - de Vlas, Sake J.
TI  - Reducing societal impacts of SARS-CoV-2 interventions through subnational implementation
AID  - 10.1101/2022.03.31.22273222
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.31.22273222
4099  - http://medrxiv.org/content/early/2022/03/31/2022.03.31.22273222.short
4100  - http://medrxiv.org/content/early/2022/03/31/2022.03.31.22273222.full
AB  - To curb the initial spread of SARS-CoV-2, many countries relied on nation-wide implementation of non-pharmaceutical interventions, at a high socio-economic cost. Using the first COVID-19 wave in the Netherlands as a case in point, we address how subnational implementations might have achieved similar levels of epidemiological control with fewer societal consequences; e.g., parts of the country could have stayed open for longer. To this end, we develop a high-resolution analysis framework reflecting a demographically stratified population with a spatially explicit, dynamic, individual contact pattern-based epidemiology, exploiting mobility trends extracted from mobile phone signals and Google mobility. The framework is exportable to other countries and settings, and may be used to develop policies on subnational approach as a better strategic choice for controlling future epidemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge financial support via ZonMw grant 10430022010001. In addition, LEC acknowledges funding from the Dutch Research Council (NWO, grant 016.Veni.178.023).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with mobility and mixing reductions (Google mobility and PIENTER) is publicly available [17, 34]. Age-stratified mixing matrices used in the analysis (POLYMOD) are publicly available as described in [9]. Hospital admission data (NICE) is publicly available as described in SI A.5. Our analysis also uses mobility information from Mezuro as input. This data is owned by a commercial party and can therefore not be made public.